Abstract
A 68-year-old male was admitted due to fatigue and poor appetite and diagnosed pathologically as pancreatic adenocarcinoma with liver metastasis. The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (Penpulimab). However, the tumor did not shrink and the tumor marker CA199 level was even higher; then anlotinib was added to therapeutic regimen. After another 4 cycles of combined treatment the size of primary tumor and metastatic lesions were significantly reduced. Laparoscopic distal panceatectomy and splenectomy as well as liver metastasis resection was performed. Three cycles of combined therapy were adopted after surgery followed by maintained therapy with anlotinib plus Penpulimab. There was no evidence of tumor recurrence 19 months since diagnosis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
